Clovis Oncology (CLVS) Shares are Down -3.1%

Clovis Oncology (CLVS) has risen sharply, recording gains of 17.23% in the past 4 weeks. However, the stock has corrected -3.1% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 16.04% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 12.79% and the 50-Day Moving Average is 15.53%. Clovis Oncology (NASDAQ:CLVS): stock turned positive on Friday. Though the stock opened at $16.12, the bulls momentum made the stock top out at $16.925 level for the day. The stock recorded a low of $15.87 and closed the trading day at $16.87, in the green by 4.07%. The total traded volume for the day was 862,937. The stock had closed at $16.21 in the previous days trading.


The company Insiders own 17.4% of Clovis Oncology shares according to the proxy statements. Institutional Investors own 97.1% of Clovis Oncology shares. Also, SunTrust Robinson Humphrey initiates coverage on Clovis Oncology (NASDAQ:CLVS) The current rating of the shares is Buy. The rating by the firm was issued on August 5, 2016.

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.